Emergent Biosolutions Inc (NYSE:EBS), reported total revenue for Q1 2014 of $53.9 million as compared to $43.1 million in 2013. In addition, Q1 2014 net loss was $20.2 million, or $0.55 per share, as compared to a net loss of $8.1 million, or $0.22 per share, in 2013. The Q1 2014 adjusted net loss was $14.6 million as compared to an adjusted net loss of $6.7 million in 2013. Emergent Biosolutions Inc (NYSE:EBS), net profit margin is 5.90% and weekly performance is -16.98%. On last trading day company shares ended up $21.52. Analysts mean target price for the company is $33.50. Emergent Biosolutions Inc (NYSE:EBS),distance from 50-day simple moving average (SMA50) is -15.84%.
On May 06, 2014, Pain Therapeutics, Inc. (NASDAQ:PTIE), reported financial results for Q1 2014. Net loss in Q1 2014 was $3.5 million, or $0.08 per share, compared to a net loss in Q1 2013 of $0.4 million, or $0.01 per share. Net cash used in Q1 2014 was $2.7 million. At March 31, 2014, cash and investments were $47.1 million. As previously disclosed, the Company believes net cash usage for 2014 may be approximately $12 million. Pain Therapeutics, Inc. (NASDAQ:PTIE), fell 7.30% in last trading session and ended the day on $4.70. PTIE, return on assets is 60.00%.
Osiris Therapeutics, Inc. (NASDAQ:OSIR), announced its financial results for the first quarter of 2014. roduct revenues during the first quarter of 2014 were $10.1 million, compared to $4.1 million during the first quarter of 2013, an increase of 146%. Gross margin during the first quarter was 78% compared to 72% during the first quarter of 2013. Gross profit was $7.8 million during the first quarter of 2014 and $2.9 million during the same period of 2013. The net loss from continuing operations was $0.6 million in the first quarter of 2014 compared to $0.3 million during the first quarter of 2013. As of March 31, 2014, Osiris had $91.3 million of total assets. Osiris Therapeutics, Inc. (NASDAQ:OSIR), shares moved down 6.11% in last trading session and was closed at $14.75, while trading in range of $14.36 – 15.67. Osiris Therapeutics, Inc. (NASDAQ:OSIR), year to date (YTD) performance is -8.27%.
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), announced its earnings results on Monday. The company reported ($0.85) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.37) by $0.48, StockRatingsNetwork reports. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), ended the last trading day at $34.04. Company weekly volatility is calculated as 8.64% and price to cash ratio as 19.15. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), showed a negative weekly performance of -11.68%.